1 Min Read
Oct 4 (Reuters) - Dimension Therapeutics Inc
* Dimension Therapeutics announces orphan drug designation of DTX401 for the treatment of glycogen storage disease type IA (GSDIA) Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.